Education
About Us
Working with TipRanks
Follow Us
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (HK:2563)
:2563
2563 Stock Chart & Stats
HK$6.36
HK$0.54(3.44%)
At close: 4:00 PM EST
HK$6.36
HK$0.54(3.44%)
Day’s Range― - ―
52-Week RangeHK$2.40 - HK$39.50
Previous CloseN/A
Volume105.40K
Average Volume (3M)341.89K
Market Cap
HK$726.01M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding216,720,860
10 Day Avg. Volume819,708
30 Day Avg. Volume341,889
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Beijing Biostar Pharmaceuticals Co., Ltd. Class H News
2563 FAQ
What was Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$2.40 and its highest was HK$39.50 in the past 12 months.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap is HK$726.01M.
When is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date is Aug 28, 2025 which is 67 days ago.
How were Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Beijing Biostar Pharmaceuticals Co., Ltd. Class H overvalued?
According to Wall Street analysts Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price is currently Overvalued.
Does Beijing Biostar Pharmaceuticals Co., Ltd. Class H pay dividends?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H does not currently pay dividends.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Biostar Pharmaceuticals Co., Ltd. Class H have?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H has 216,720,860 shares outstanding.
What happened to Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Beijing Biostar Pharmaceuticals Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2563
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co. Ltd. engages in the provision of treatment for tumor. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) Earnings & Revenues
Technical Analysis
Tianda Pharmaceuticals Ltd.
―
Ocumension Therapeutics
―
Fusen Pharmaceutical Co., Ltd.
―
Ascletis Pharma, Inc.
―
China Shineway Pharmaceutical Group Limited
―